http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 09:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SC+TO-TA++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+Chiesi+Farmaceutici+SpA/26580444.html si-local-file:///var/storage/secattach/20260601/26580444.html http://www.streetinsider.com/SEC+Filings/Form++SC+TO-TA++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+Chiesi+Farmaceutici+SpA/26580444.html Mon, 01 Jun 2026 09:06:00 -0400 KALV O.22231887 http://www.streetinsider.com/SEC+Filings/Form++SC+TO-TA++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+Chiesi+Farmaceutici+SpA/26580444.html si-local-file:///var/storage/secattach/20260601/26580444.html http://www.streetinsider.com/SEC+Filings/Form++SC+TO-TA++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+Chiesi+Farmaceutici+SpA/26580444.html Mon, 01 Jun 2026 09:06:00 -0400 KALV O.22231887 http://www.streetinsider.com/SEC+Filings/Form++SC+14D9A++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+KalVista+Pharmaceuticals%2C+Inc./26580441.html si-local-file:///var/storage/secattach/20260601/26580441.html http://www.streetinsider.com/SEC+Filings/Form++SC+14D9A++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+KalVista+Pharmaceuticals%2C+Inc./26580441.html Mon, 01 Jun 2026 09:05:00 -0400 KALV O.22231887 http://www.streetinsider.com/SEC+Filings/Form++SC+14D9A++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+KalVista+Pharmaceuticals%2C+Inc./26580441.html si-local-file:///var/storage/secattach/20260601/26580441.html http://www.streetinsider.com/SEC+Filings/Form++SC+14D9A++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+KalVista+Pharmaceuticals%2C+Inc./26580441.html Mon, 01 Jun 2026 09:05:00 -0400 KALV O.22231887 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++KalVista+Pharmaceuticals++For%3A+May+27++Filed+by%3A+Yea+Christopher/26575025.html si-local-file:///var/storage/secattach/20260529/26575025.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++KalVista+Pharmaceuticals++For%3A+May+27++Filed+by%3A+Yea+Christopher/26575025.html Fri, 29 May 2026 16:05:00 -0400 KALV O.22231887 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++KalVista+Pharmaceuticals++For%3A+May+27++Filed+by%3A+Yea+Christopher/26575025.html si-local-file:///var/storage/secattach/20260529/26575025.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++KalVista+Pharmaceuticals++For%3A+May+27++Filed+by%3A+Yea+Christopher/26575025.html Fri, 29 May 2026 16:05:00 -0400 KALV O.22231887 http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Press+Releases/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html <p class="bwalignc"> <i>Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE</i> </p> <p> FRAMINGHAM, Mass. &amp; SALISBURY, England--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54543154&amp;newsitemid=20260528516882&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b72e371d20e0eb43f2e6e31a4ec609a2" shape="rect">KalVista Pharmaceuticals</a>, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). </p><p> “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben http://www.streetinsider.com/Business+Wire/KalVista+Pharmaceuticals+Presents+New+Data+Highlighting+the+Burden+of+Injectable+On-Demand+Treatment+in+Young+Children+with+Hereditary+Angioedema/26560954.html Thu, 28 May 2026 07:00:00 -0400 A.18406154 A.39148112 A.50213590 KALV O.10437307 O.16087478 O.22231887 O.25213126 http://www.streetinsider.com/SEC+Filings/Form++144++++++++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+Yea+Christopher/26559160.html si-local-file:///var/storage/secattach/20260527/26559160.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+Yea+Christopher/26559160.html Wed, 27 May 2026 17:19:00 -0400 KALV O.22231887 http://www.streetinsider.com/SEC+Filings/Form++144++++++++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+Yea+Christopher/26559160.html si-local-file:///var/storage/secattach/20260527/26559160.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++KalVista+Pharmaceuticals+++++++++++++++Filed+by%3A+Yea+Christopher/26559160.html Wed, 27 May 2026 17:19:00 -0400 KALV O.22231887 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++KalVista+Pharmaceuticals++For%3A+May+22++Filed+by%3A+Sweeny+Nicole/26557787.html si-local-file:///var/storage/secattach/20260527/26557787.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++KalVista+Pharmaceuticals++For%3A+May+22++Filed+by%3A+Sweeny+Nicole/26557787.html Wed, 27 May 2026 16:06:00 -0400 KALV O.22231887